Yesterday, a Director at Tandem Diabetes Care (TNDM), Kim Blickenstaff, bought shares of TNDM for $7.48M.
Following this transaction Kim Blickenstaff’s holding in the company was increased by 2164.54% to a total of $87.61 million. Following Kim Blickenstaff’s last TNDM Buy transaction on January 31, 2020, the stock climbed by 24.2%.
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes Care’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $97.93 million and GAAP net loss of -$14,867,000. In comparison, last year the company earned revenue of $93.26 million and had a GAAP net loss of $1.51 million. The company has a one-year high of $110.80 and a one-year low of $43.69. The Company has a Price to Book ratio of 23.70.
Based on 13 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $118.23, reflecting a -15.9% downside. Eight different firms, including Citigroup and Cowen & Co., currently also have a Buy rating on the stock. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy TNDM with a $125.00 price target.
In the last 30 days, insiders have sold $36.25M worth of TNDM shares and purchased $7.48M worth of TNDM shares. The insider sentiment on Tandem Diabetes Care has been negative according to 70 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
